{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:19:48Z","timestamp":1764494388464,"version":"3.41.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec0123\">\n<jats:title>Background<\/jats:title>\n<jats:p>Previous studies have shown that body composition influences the prognosis of heart failure patients; however, the prognostic value of lean body mass and fat mass in patients with heart failure with preserved ejection fraction (HFpEF) remains unclear. This study aimed to investigate the association of lean body mass index and fat mass index with the prognostic outcomes in patients with HFpEF.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec0124\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We performed a post hoc analysis of data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial to assess the relationship between Lean BMI and FMI with the adverse events. The primary endpoint was defined as a composite of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec0125\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 3,320 patients were included, with a median follow-up of 3.3 years. Among them, 624 occurred a primary endpoint event, and 503 died. Lean BMI was not associated with the primary endpoint (HR 0.98, 95% CI 0.82\u20131.16) but was found to reduce the risk of all-cause mortality (HR 0.74, 95% CI 0.61\u20130.91). In contrast, FMI was associated with an increased risk of both the primary endpoint (HR 1.29, 95% CI 1.09\u20131.55) and all-cause mortality (HR 1.46, 95% CI 1.19\u20131.79).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec0126\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In patients with HFpEF, a higher FMI was strongly associated with increased risks of both the primary endpoint and all-cause mortality, while an elevated LBMI was associated with a reduced risk of mortality.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0323634","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:55:12Z","timestamp":1748627712000},"page":"e0323634","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of predicted lean body mass and fat mass with prognosis in patients with heart failure preserved ejection fraction"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0604-7603","authenticated-orcid":true,"given":"Wen","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8628-030X","authenticated-orcid":true,"given":"Junyu","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenfei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"1","key":"pone.0323634.ref001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"CE Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"pone.0323634.ref002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes","volume":"126","author":"BA Steinberg","year":"2012","journal-title":"Circulation"},{"key":"pone.0323634.ref003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pcad.2024.01.003","article-title":"Update on obesity, the obesity paradox, and obesity management in heart failure","volume":"82","author":"PL Alebna","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"pone.0323634.ref004","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.trsl.2014.04.010","article-title":"Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management","volume":"164","author":"MA Alpert","year":"2014","journal-title":"Transl Res"},{"key":"pone.0323634.ref005","first-page":"101162","article-title":"Adiposity and clinical outcomes in East Asian patients with heart failure and preserved ejection fraction","volume":"44","author":"Y Seki","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"pone.0323634.ref006","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijcard.2022.05.018","article-title":"Association of body mass index and prognosis in patients with HFpEF: A dose-response meta-analysis","volume":"361","author":"S Li","year":"2022","journal-title":"Int J Cardiol"},{"issue":"2","key":"pone.0323634.ref007","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.mayocp.2016.11.001","article-title":"Obesity and Heart Failure: Focus on the Obesity Paradox","volume":"92","author":"S Carbone","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"pone.0323634.ref008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ahj.2022.12.008","article-title":"Predicted lean body mass, fat mass, and heart failure in patients with type 2 diabetes mellitus","volume":"257","author":"X Tang","year":"2023","journal-title":"Am Heart J"},{"key":"pone.0323634.ref009","doi-asserted-by":"crossref","first-page":"824628","DOI":"10.3389\/fcvm.2022.824628","article-title":"Association of Lean Body Mass and Fat Mass With 1-Year Mortality Among Patients With Heart Failure","volume":"9","author":"Y Ge","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"38","key":"pone.0323634.ref010","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.190124","article-title":"Association of predicted lean body mass and fat mass with cardiovascular events in patients with type 2 diabetes mellitus","volume":"191","author":"Z Xing","year":"2019","journal-title":"CMAJ"},{"issue":"9","key":"pone.0323634.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002916","article-title":"Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study","volume":"16","author":"C Chandramouli","year":"2019","journal-title":"PLoS Med"},{"issue":"15","key":"pone.0323634.ref012","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"B Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0323634.ref013","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1017\/S0007114517002665","article-title":"Development and validation of anthropometric prediction equations for lean body mass, fat mass and percent fat in adults using the National Health and Nutrition Examination Survey (NHANES) 1999-2006","volume":"118","author":"DH Lee","year":"2017","journal-title":"Br J Nutr"},{"issue":"6","key":"pone.0323634.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"AS Desai","year":"2011","journal-title":"Am Heart J"},{"issue":"2","key":"pone.0323634.ref015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ehf2.14595","article-title":"Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction","volume":"11","author":"W Li","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"1","key":"pone.0323634.ref016","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12933-024-02430-9","article-title":"The role of body composition in left ventricular remodeling, reverse remodeling, and clinical outcomes for heart failure with mildly reduced ejection fraction: more knowledge to the \u201cobesity paradox\u201d","volume":"23","author":"K Fu","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"pone.0323634.ref017","article-title":"Novel adiposity indices are associated with poor prognosis in heart failure with preserved ejection fraction without the obesity paradox","author":"S Zhang","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"pone.0323634.ref018","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity","volume":"16","author":"R Ross","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"15","key":"pone.0323634.ref019","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/2047487319851298","article-title":"Threshold body mass index and sex-specific waist circumference for increased risk of heart failure with preserved ejection fraction","volume":"26","author":"DJ Campbell","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"22","key":"pone.0323634.ref020","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jacc.2017.09.1111","article-title":"Abdominal obesity is associated with an increased risk of all-cause mortality in patients with hfpef","volume":"70","author":"T Tsujimoto","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0323634.ref021","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pcad.2017.07.001","article-title":"Exercise Training for Prevention and Treatment of Heart Failure","volume":"60","author":"N Kondamudi","year":"2017","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"pone.0323634.ref022","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/clc.23970","article-title":"Prevalence of sarcopenia and its association with clinical outcomes in heart failure: An updated meta-analysis and systematic review","volume":"46","author":"R Chen","year":"2023","journal-title":"Clin Cardiol"},{"issue":"1","key":"pone.0323634.ref023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"3","key":"pone.0323634.ref024","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11897-015-0257-5","article-title":"Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction","volume":"12","author":"B Upadhya","year":"2015","journal-title":"Curr Heart Fail Rep"},{"key":"pone.0323634.ref025","doi-asserted-by":"crossref","first-page":"155577","DOI":"10.1016\/j.metabol.2023.155577","article-title":"Interplay of skeletal muscle and adipose tissue: sarcopenic obesity","volume":"144","author":"MJ Park","year":"2023","journal-title":"Metabolism"},{"key":"pone.0323634.ref026","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13098-020-0523-x","article-title":"Mechanism of increased risk of insulin resistance in aging skeletal muscle","volume":"12","author":"J Shou","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"10","key":"pone.0323634.ref027","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2213-8587(14)70034-8","article-title":"Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases","volume":"2","author":"RR Kalyani","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"pone.0323634.ref028","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacbts.2024.07.009","article-title":"Exercise Therapy Rescues Skeletal Muscle Dysfunction and Exercise Intolerance in Cardiometabolic HFpEF","volume":"9","author":"H Quiriarte","year":"2024","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"pone.0323634.ref029","doi-asserted-by":"crossref","first-page":"22505","DOI":"10.1038\/s41598-024-72965-0","article-title":"Differential impacts of body composition on oxygen kinetics and exercise tolerance of HFrEF and HFpEF patients","volume":"14","author":"Jr Cipriano G","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0323634.ref030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"MA Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"pone.0323634.ref031","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors","volume":"12","author":"R Patel","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"12","key":"pone.0323634.ref032","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"MN Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0323634.ref033","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"ME Nassif","year":"2021","journal-title":"Nat Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:55:21Z","timestamp":1748627721000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323634"}},"subtitle":[],"editor":[{"given":"Amir Hossein","family":"Behnoush","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0323634","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}